NCT02627287 is a Phase 1 clinical trial of FlexPen® in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02627287?

NCT02627287 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02627287?

Interventions in NCT02627287: FlexPen®, DV3316 pen-injector, placebo.

What condition does NCT02627287 study?

NCT02627287 studies Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.

Is NCT02627287 still recruiting?

NCT02627287 is currently completed. Last updated 7 February 2018.

Last reviewed 2018-02-07 · How we verify

NCT02627287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

Completed Phase 1 Last updated 7 February 2018

What this trial tests

Phase 1 trial testing FlexPen® in Diabetes in 150 participants. Completed in 25 February 2016.

Timeline

1 December 2015

Primary endpoint
25 February 2016

25 February 2016

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	other
Enrollment	150
Start date	1 December 2015
Primary completion	25 February 2016
Estimated completion	25 February 2016
Sites	2 locations across Germany

Drugs / interventions tested

FlexPen®
DV3316 pen-injector
placebo

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 74, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe. The aim of this trial is to compare Injections with the Medical Device DV3316 Pen-injector versus FlexPen®.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.
Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, et al · · 2018 · cited 4× · PMID 29369493 · DOI 10.1111/dom.13203

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02627287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 7 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02627287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing